{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:13:37Z","timestamp":1783498417008,"version":"3.55.0"},"reference-count":43,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly used for glycemic control in patients with type 2 diabetes and for weight loss in obese patients, have been increasingly used due to their effectiveness in treating these conditions and in reducing cardiovascular events. Yet evidence is limited surrounding their impact on bone health and on patients undergoing orthopedic procedures. This narrative review explores the mechanisms of action of GLP-1 agonists, their effects on bone health, and the implications of their use in perioperative patents undergoing orthopedic surgery, with an emphasis on spine surgery. Basic science studies suggest that GLP-1 agonists may enhance bone mineral density and reduce bone resorption through various molecular pathways; clinical studies of their impact on fracture risk and bone health show mixed results. Also, the perioperative use of GLP-1 agonists poses challenges due to their effects on gastric motility and potential medication interactions. Nonetheless, achieving proper glycemic control with GLP-1 agonists may benefit patients with diabetes or obesity undergoing orthopedic procedures, particularly in preoperative weight management and glycemic control. Further research is needed to clarify their long-term effects on bone health and their perioperative use in orthopedic patients.<\/jats:p>","DOI":"10.1177\/15563316261438492","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:56:51Z","timestamp":1778734611000},"page":"394-401","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications"],"prefix":"10.1177","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0457-3308","authenticated-orcid":false,"given":"Mateo","family":"Restrepo Mejia","sequence":"first","affiliation":[{"name":"Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9414-7120","authenticated-orcid":false,"given":"Justin","family":"Tiao","sequence":"additional","affiliation":[{"name":"Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Yu","sequence":"additional","affiliation":[{"name":"Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joydeep","family":"Baidya","sequence":"additional","affiliation":[{"name":"College of Medicine, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moutie","family":"Rajjoub","sequence":"additional","affiliation":[{"name":"Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodnell","family":"Busigo Torres","sequence":"additional","affiliation":[{"name":"Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5305-3785","authenticated-orcid":false,"given":"Saad B.","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Leni and Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Montero A Brodie M Perry M. KFF health tracking poll May 2024: the public\u2019s use and views of GLP-1 drugs. 2024. Accessed June 15 2024. https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Kazafeos K. Incretin effect: GLP-1 GIP DPP4. Diabetes Res Clin Pract. 2011;93(suppl 1):S32-S36. https:\/\/doi.org\/10.1016\/S0168-8227(11)70011-0","DOI":"10.1016\/S0168-8227(11)70011-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(suppl 2):S279-S284. https:\/\/doi.org\/10.2337\/dc11-S231","DOI":"10.2337\/dc11-s231"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202-210. https:\/\/doi.org\/10.2337\/ds16-0021","DOI":"10.2337\/ds16-0026"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Acosta A Camilleri M Burton D. Exenatide in obesity with accelerated gastric emptying: a randomized pharmacodynamics study. Physiol Rep. 2015;3(11):e12610. https:\/\/doi.org\/10.14814\/phy2.12610","DOI":"10.14814\/phy2.12610"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Jackson KLII Devine JG. The effects of obesity on spine surgery: a systematic review of the literature. Global Spine J. 2016;6(4):394-400. https:\/\/doi.org\/10.1055\/s-0035-1570750","DOI":"10.1055\/s-0035-1570750"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Cirnigliaro CM LaFountaine MF Chen Y. Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: a controlled case series. J Spinal Cord Med. 2024;47(4):597-605. https:\/\/doi.org\/10.1080\/10790268.2023.2205480","DOI":"10.1080\/10790268.2023.2207064"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Ghusn W De la Rosa A Sacoto D et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5(9):e2231982. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31982","DOI":"10.1001\/jamanetworkopen.2022.31982"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Sanz C Vazquez P Blazquez C Barrio PA Alvarez P Blazquez E. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab. 2010;298(3):E634-E643. https:\/\/doi.org\/10.1152\/ajpendo.00460.2009","DOI":"10.1152\/ajpendo.00460.2009"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Luo G Liu H Lu H. Glucagon-like peptide-1 receptor agonists: potential to reduce fracture risk in diabetic patients?. Br J Clin Pharmacol. 2016;81(1):78-88. https:\/\/doi.org\/10.1111\/bcp.12777","DOI":"10.1111\/bcp.12777"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Yamada C Yamada Y Tsukiyama K. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149(2):574-579. https:\/\/doi.org\/10.1210\/en.2007-1292","DOI":"10.1210\/en.2007-1292"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Crespel A De Boisvilliers F Gros L Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology. 1996;137(9):3674-3680. https:\/\/doi.org\/10.1210\/endo.137.9.8756532","DOI":"10.1210\/endo.137.9.8756532"},{"issue":"8","key":"e_1_3_2_14_2","first-page":"4800","article-title":"Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis","volume":"11","author":"Mei J","year":"2019","unstructured":"Mei J, Sun J, Wu J, Zheng X. Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. Am J Transl Res. 2019;11(8):4800-4808.","journal-title":"Am J Transl Res"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Li H Chen J Li B Fang X. The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type \u2161 collagen and aggrecan in human SW1353 chondrocytes. Chem Biol Interact. 2020;322:108968. https:\/\/doi.org\/10.1016\/j.cbi.2020.108968","DOI":"10.1016\/j.cbi.2020.108968"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Mabilleau G Mieczkowska A Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes. 2014;6(3):260-266. https:\/\/doi.org\/10.1111\/1753-0407.12102","DOI":"10.1111\/1753-0407.12102"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Driessen JH Onzenoort HA Starup-Linde J. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int. 2015;97(2):104-112. https:\/\/doi.org\/10.1007\/s00223-015-9993-5","DOI":"10.1007\/s00223-015-9993-5"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Cheng L Hu Y Li YY et al. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2019;35(7):e3168. https:\/\/doi.org\/10.1002\/dmrr.3168","DOI":"10.1002\/dmrr.3168"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Al-Mashhadi ZK Viggers R Fuglsang-Nielsen R Vestergaard P Gregersen S Starup-Linde J. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: a Danish nationwide cohort study. Front Endocrinol. 2022;13:882998. https:\/\/doi.org\/10.3389\/fendo.2022.882998","DOI":"10.3389\/fendo.2022.882998"},{"issue":"1","key":"e_1_3_2_20_2","first-page":"142","article-title":"Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density","volume":"21","author":"Chen K","year":"2021","unstructured":"Chen K, Wu R, Mo B, Yan X, Shen D, Chen M. Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density. J Musculoskelet Neuronal Interact. 2021;21(1):142-148.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Jensen SBK S\u00f8rensen V Sandsdal RM et al. Bone health after exercise alone GLP-1 receptor agonist treatment or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.16775","DOI":"10.1001\/jamanetworkopen.2024.16775"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Iepsen EW Lundgren JR Hartmann B et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100(8):2909-2917. https:\/\/doi.org\/10.1210\/jc.2015-1176","DOI":"10.1210\/jc.2015-1176"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Shin JI Phan K Kothari P Kim JS Guzman JZ Cho SK. Impact of glycemic control on morbidity and mortality in adult idiopathic scoliosis patients undergoing spinal fusion. Clin Spine Surg. 2017;30(7):E974-E980. https:\/\/doi.org\/10.1097\/BSD.0000000000000447","DOI":"10.1097\/BSD.0000000000000447"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Tanaka T Bradford T Litofsky NS. Severity of preoperative HbA1c and predicting postoperative complications in spine surgery. World Neurosurg. 2021;155:e119-e126. https:\/\/doi.org\/10.1016\/j.wneu.2021.08.133","DOI":"10.1016\/j.wneu.2021.08.133"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Clement S Braithwaite SS Magee MF et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553-591. https:\/\/doi.org\/10.2337\/diacare.27.2.553","DOI":"10.2337\/diacare.27.2.553"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Klein SR Hobai IA. Semaglutide delayed gastric emptying and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023;70(8):1014-1016. https:\/\/doi.org\/10.1007\/s12630-023-02440-3","DOI":"10.1007\/s12630-023-02440-3"},{"key":"e_1_3_2_27_2","volume-title":"StatPearls","author":"Dogra P","year":"2024","unstructured":"Dogra P, Anastasopoulou C, Jialal I. Diabetic perioperative management. In: StatPearls (Internet). StatPearls Publishing; 2024."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Kittner SL Lee D Walker J. Retained gastric contents after adequate fasting associated with GLP-1 receptor agonist use: a report of 3 cases. JBJS Case Connect. 2023;13(4):506. https:\/\/doi.org\/10.2106\/JBJS.CC.23.00506","DOI":"10.2106\/JBJS.CC.23.00506"},{"key":"e_1_3_2_29_2","unstructured":"American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. ASA Newsroom. 2024. Accessed July 3 2024. https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Joshi GP. Anesthetic considerations in adult patients on glucagon-like peptide-1 receptor agonists: gastrointestinal focus. Anesth Analg. 2024;138(1):45-52. https:\/\/doi.org\/10.1213\/ANE.0000000000006810","DOI":"10.1213\/ANE.0000000000006810"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Ma J Rayner CK Jones KL Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs. 2009;69(8):971-986. https:\/\/doi.org\/10.2165\/00003495-200969080-00003","DOI":"10.2165\/00003495-200969080-00003"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Dixit AA Rosenman ED Zhang Y. Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications. JAMA. 2024;331(19):1672-1673. https:\/\/doi.org\/10.1001\/jama.2024.2541","DOI":"10.1001\/jama.2024.5003"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Diaz R DeJesus J. Managing patients undergoing orthopedic surgery to improve glycemic outcomes. Curr Diab Rep. 2022;21(12):34-41. https:\/\/doi.org\/10.1007\/s11892-021-01434-z","DOI":"10.1007\/s11892-021-01434-z"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Gracia-Ramos AE Perez-Sanchez J Rios-Morales M. Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients. Curr Med Res Opin. 2022;38(1):43-55. https:\/\/doi.org\/10.1080\/03007995.2021.1997288","DOI":"10.1080\/03007995.2021.1997288"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Mendez CE Umpierrez GE. Pharmacotherapy for hyperglycemia in noncritically ill hospitalized patients. Diabetes Spectr. 2014;27(3):180-186. https:\/\/doi.org\/10.2337\/diaspect.27.3.180","DOI":"10.2337\/diaspect.27.3.180"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Bethel MA Patel RA Merrill P. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105-113. https:\/\/doi.org\/10.1016\/S2213-8587(17)30412-6","DOI":"10.1016\/S2213-8587(17)30412-6"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Vatsia SK Levidy MF Rowe ND Meister AS Bible JE. Fusion outcomes of GLP-1 agonist therapy in multilevel cervical spinal fusion: a propensity-matched analysis. Clin Spine Surg. 2025;38(4):213-216. https:\/\/doi.org\/10.1097\/BSD.0000000000001775","DOI":"10.1097\/BSD.0000000000001775"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Agrawal V Amasa S Karabacak M Margetis K. Perioperative glucagon-like peptide-1 agonist use and rates of pseudarthrosis after single-level lumbar fusion: a large retrospective cohort study. Neurosurgery. 2024;97(1):91-97. https:\/\/doi.org\/10.1227\/neu.0000000000003291","DOI":"10.1227\/neu.0000000000003291"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Chang Y Lin HM Chi KY Song J Atwan H. The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes. Int J Surg. 2025;111(7):4898-4900. https:\/\/doi.org\/10.1097\/JS9.0000000000002492","DOI":"10.1097\/JS9.0000000000002492"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Wiener JM Sanghvi PA Vlastaris K et al. Glucagon-like peptide-1 receptor agonist medications alter outcomes of spine surgery: a study among over 15 000 patients. Spine. 2025;50(13):871-880. https:\/\/doi.org\/10.1097\/BRS.0000000000005283","DOI":"10.1097\/BRS.0000000000005283"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Calvarysky B Pardo F Nunez C. Drug-drug interactions between glucagon-like peptide-1 receptor agonists and oral medications: a systematic review. Drug Saf. 2024;47(5):435-448. https:\/\/doi.org\/10.1007\/s40264-023-01392-3","DOI":"10.1007\/s40264-023-01392-3"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Meneghini LF. Perioperative management of diabetes: translating evidence into practice. Cleve Clin J Med. 2009;76(suppl 4):S53-S59. https:\/\/doi.org\/10.3949\/ccjm.76.s4.09","DOI":"10.3949\/ccjm.76.s4.09"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Meier JJ Gallwitz B Salmen S. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes. 2005;54(7):2212-2218. https:\/\/doi.org\/10.2337\/diabetes.54.7.2212","DOI":"10.2337\/diabetes.54.7.2212"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Zhang Y Ji Y Zhang W. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. Neuropsychopharmacology. 2020;45(3):477-486. https:\/\/doi.org\/10.1038\/s41386-019-0531-4","DOI":"10.1038\/s41386-019-0531-4"}],"container-title":["HSS Journal\u00ae: The Musculoskeletal Journal of Hospital for Special Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15563316261438492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15563316261438492","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15563316261438492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:17:50Z","timestamp":1783495070000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15563316261438492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/15563316261438492"],"URL":"https:\/\/doi.org\/10.1177\/15563316261438492","relation":{},"ISSN":["1556-3316","1556-3324"],"issn-type":[{"value":"1556-3316","type":"print"},{"value":"1556-3324","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}